$0.61
arrow_drop_down1.90%Key Stats | |
---|---|
Open | $0.63 |
Prev. Close | $0.63 |
EPS | -1.74 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $23.64M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 0.61 | 0.63 |
52 Week Range | 0.60 | 1.56 |
Ratios | |
---|---|
EPS | -1.74 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
BOLT DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action – BOLT
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
BOLT FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action – BOLT
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm